Group 1 - The supervisory board of Shanghai Kelly Tai Medical Technology Co., Ltd. held its 22nd meeting and confirmed that the procedures for preparing and reviewing the 2025 semi-annual report comply with legal and regulatory requirements, ensuring the report accurately reflects the company's actual situation without any false statements or omissions [1][2] - The board approved a proposal for daily related transactions with associated companies, estimating a total amount not exceeding 30.55 million yuan (excluding tax) for 2025, compared to an actual transaction amount of 28.77 million yuan in 2024 [1][2] - The company reported an excess of 3.24 million yuan in daily related transactions for 2024, with specific excesses in service categories and sales to related parties [1][2] Group 2 - The management is authorized to conduct daily transactions within the approved amount, and any excess will require re-evaluation by the board or shareholders according to the Shenzhen Stock Exchange regulations [2] - The announcement regarding the recognition of excess related transactions for 2024 and the estimated transactions for 2025 is available on the designated information disclosure website [2] - The supervisory board's resolution document is available for review [2]
ST凯利: 监事会决议公告